


PE/Cy7 anti-human IFN- γ

Catalog # / Size:	3112635 / 25 tests 3112640 / 100 tests
Clone:	4S.B3
Isotype:	Mouse IgG1, κ
Immunogen:	Partially purified, native human IFN- γ
Reactivity:	Human
Preparation:	The antibody was purified by affinity chromatography, and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
Concentration:	Lot-specific



PMA/ionomycin-stimulated (5 hours) human peripheral blood lymphocytes intracellularly stained with 4S.B3 PE/Cy7 and CD4 (RPA-T4) PE

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microL to 5 microL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: **ELISA or ELISPOT Detection⁵:** The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402/502404) or purified MD-1 antibody (Cat. No. 507502/507513) as the capture antibody.

Flow Cytometry^{3,4,6-8}: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN- γ -producing cells within mixed cell populations.

Additional reported applications (for the relevant formats) include: neutralization^{1,2}, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN- γ .

Note: For testing human IFN- γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.

- Application References:**
1. Meager A, *et al.* 1984. *J. Interferon Res.* 4:619. (Neut)
 2. Meager A, 1987. *Lymphokines and Interferons: A Practical Approach.* IRL Press Ltd, Oxford, p. 105. (Neut)
 3. Sester M, *et al.* 2002. *J. Virol.* 76:3748. (ICFC)
 4. Infante-Duarte C, *et al.* 2000 *J. Immunol.* 165:6107. (ICFC)
 5. Goodier M, *et al.* 2000. *J. Immunol.* 165:139. (ELISA)
 6. Chen H, *et al.* 2005. *J. Immunol.* 175:591. (ICFC)
 7. Smeltz RB, 2007. *J. Immunol.* 178:4786. (ICFC)
 8. Iwamoto S, *et al.* 2007. *J. Immunol.* 179:1449. (ICFC) [PubMed](#)
 9. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (ICFC)

10. Brembilla NC, *et al.* 2011. *PLoS One*. 15:18741. [PubMed](#)
 11. Jiang B, *et al.* 2014. *Cell Immunol*. 290:10. [PubMed](#)
 12. Lim DS, *et al.* 2014. *J Immunol*. 193:5065. [PubMed](#)
-

Description: Interferon- γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN- γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN- γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Antigen References:

1. Fitzgerald K, *et al.* Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, *et al.* 1992. *Curr. Opin. Immunol*. 4:321.
3. Farrar M, *et al.* 1993. *Annu. Rev. Immunol*. 11:571